Portal de Periódicos da CAPES

Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study

2016; Adis, Springer Healthcare; Volume: 17; Issue: 2 Linguagem: Inglês

10.1007/s40256-016-0197-9

1179-187X

Jesús Millán Núñez-Cortés, Aleix Cases, Juan Francisco Ascaso Gimilio, Vivencio Barrios, Vicente Pascual Fuster, Juan Carles Pedro-Botet Montoya, Xavier Pintó, A. Serrano Cumplido,

Pharmaceutical Practices and Patient Outcomes

Despite the recognized clinical benefit of statins on cardiovascular prevention, providing correct management of hypercholesterolaemia, possible adverse effects of their use cannot be disregarded. Previously published data shows that there is a risk of developing diabetes mellitus or experiencing changes in glucose metabolism in statin-treated patients. The possible determining factors are the drug characteristics (potency, dose), patient characteristics (kidney function, age, cardiovascular risk and polypharmacy because of multiple disorders) and the pre-diabetic state. In order to ascertain the opinion of the experts (primary care physicians and other specialists with experience in the management of this type of patient) we conducted a Delphi study to evaluate the consensus rate on diverse aspects related to the diabetogenicity of different statins, and the factors that influence their choice. Consensus was highly significant concerning aspects such as the varying diabetogenicity profiles of different statins, as some of them do not significantly worsen glucose metabolism. There was an almost unanimous consensus that pitavastatin is the safest statin in this regard. Factors to consider in the choice of a statin regarding its diabetogenicity are the dose and patient-related factors: age, cardiovascular risk, diabetes risk and baseline metabolic parameters (which must be monitored during the treatment), as well as kidney function.